Using Nadroparin to Improve Outcomes in Patients with Aneurysmal Subarachnoid Hemorrhage

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effects of therapeutic low-molecular weight heparin (Nadroparin) on patients who have experienced an aneurysmal subarachnoid hemorrhage (aSAH). The study aims to determine if higher doses of Nadroparin can reduce the 30-day mortality rate compared to standard prophylactic doses. It also seeks to explore differences in clinical outcomes related to delayed cerebral ischemia (DCI) in these patients. Participants will be monitored for their response to treatment following the coiling of the causative aneurysm.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* SAH confirmed by CT or lumbar puncture with the causative aneurysm confirmed by CT-A and/or digital subtraction angiography
* Coiling of the causative aneurysm within 72 hours of initial SAH
* Informed consent within 24 hours after coiling

Exclusion Criteria:

Stent-assisted coiling

* Use of anticoagulant medication post-coiling for other reasons
* Contra-indications for LMWH:

  * Previous history of history of heparin-induced thrombocytopenia
  * (Suspicion of) active arterial or venous bleeding
  * Previous history of hemorrhagic diathesis due to coagulation disorders (with the ex-ception of disseminated intravascular coagulation)
  * Severe hypertension: uncontrolled hypertension with a mean arterial pressure \>135mmHg
  * Previous history of hypertensive or diabetic retinopathy
  * Previous history of active infectious endocarditis
  * Severe renal impairment (creatinine clearance \<30 mL / min)
* No proficiency of Dutch or English language

Where it's running

• Amsterdam University Medical Centers
  Amsterdam, Netherlands Recruiting

Study contacts

• Study coordinator: Dagmar Verbaan, PhD
• Email: d.verbaan@amsterdamumc.nl
• Phone: +31205663316

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tocilizumab-aazg to reduce stroke risk after a ruptured brain aneurysm

  This trial will try to see if a single IV dose of tocilizumab-aazg is safe and can help prevent delayed strokes in adults who have had a ruptured brain aneurysm (aneurysmal subarachnoid hemorrhage).

  Recruiting Phase 1 University of Florida · Gainesville, Florida · NCT06863480

• Metabolomics biomarkers to predict outcomes after subarachnoid hemorrhage

  This study tests whether blood and CSF biomarkers, together with clinical data, can predict recovery a year after spontaneous subarachnoid hemorrhage in adults treated in Lisbon.

  Recruiting Unidade Local de Saude Sao Jose · Lisbon, Lisbon District · NCT07865182

• Nitric Oxide Use to Predict Vasospasm in Aneurysmal Subarachnoid Hemorrhage

  This study tests whether nitric oxide consumption in CSF can predict cerebral vasospasm in patients with aneurysmal SAH.

  Recruiting at 2 sites Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT07614906

• Multi-omics program to understand complications and outcomes after aneurysmal subarachnoid hemorrhage

  This project will test if combining blood, cerebrospinal fluid, urine, imaging, and multi-omics data can find biomarkers that predict complications and outcomes in adults with aneurysmal subarachnoid hemorrhage.

  Recruiting Beijing Tiantan Hospital · Beijing, Beijing Municipality · NCT07270419

• Dome-only coiling for severe aneurysmal subarachnoid hemorrhage

  This will test a minimally invasive dome-protection coiling procedure to prevent re-bleeding in adults who have had a severe aneurysmal subarachnoid hemorrhage.

  Recruiting University of Louisville · Louisville, Kentucky · NCT07250958

• Cilostazol to help prevent delayed brain ischemia after aneurysm bleed

  This study tests whether cilostazol can reduce delayed brain ischemia and improve outcomes after aneurysmal subarachnoid hemorrhage in adults who had recent aneurysm treatment.

  Recruiting Phase 3 Beijing Tiantan Hospital · Beijing, Beijing Municipality · NCT07249853

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.